Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Aquavit Pharmaceuticals, Inc
WARNING LETTER
•Aquavit Pharmaceuticals, Inc•December 19, 2019

Aquavit Pharmaceuticals, Inc – FDA Warning Letter, Dec 19, 2019

Record Details

The FDA issued a Warning Letter to Aquavit Life Sciences, Inc. for marketing the AQUAGOLD® fine touch and A.S.A.P! Micro Infusion System without marketing clearance or approval, violating the Federal Food, Drug, and Cosmetic Act. These products are deemed adulterated under section 501(f)(1)(B) because the firm lacks approved premarket approval (PMA) or investigational device exemption (IDE) applications. They are also misbranded under section 502(o) for failure to notify FDA of intent to introduce the devices into commercial distribution, as required by section 510(k).

The AQUAGOLD® fine touch, marketed for physician use, and the A.S.A.P! Micro Infusion System, for at-home use, are considered devices due to claims of delivering therapeutics into the dermis for medical purposes like stimulating collagen, wound healing, and treating conditions such as acne scars, hyperhidrosis, and alopecia. Both devices penetrate beyond the stratum corneum, affecting body structure/function. Microneedling devices for aesthetic use are Class II devices requiring 510(k) premarket notification, and no microneedling device is cleared for OTC/home use.

The firm also markets SKINWORKOUT® U.R. (Ultimate Radiance) and T.T. (Targeted Toning) serums, intended for injection for medical purposes, which

Company
Aquavit Pharmaceuticals, Inc
Inspection date
December 19, 2019
Product type
Devices
Office
Office of Medical Device and Radiological Health Division 1 – East
People
  • Binita S. Ashar (Director)
  • Joseph S. Matrisciano (Program Division Director)
  • Sean Moynihan
  • Gina Brackett (Director of Compliance Branch)
View Company Profile

ID · a1bbf33d-ccab-449f-99fc-5dfb5cd1fa14

Violation Codes10
21 U.S.C. 321(h)21 U.S.C. 351(f)(1)(B)21 U.S.C. 360e(a)21 U.S.C. 360j(g)21 U.S.C. 352(o)21 U.S.C. 360(k)21 U.S.C. 360j(e)21 CFR 878.443021 CFR 807.81(b)21 CFR 878.4800

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Aquavit Pharmaceuticals, Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.